Amgen Inc Investor Call Transcript

Dec 05, 2022 / 01:00PM GMT
Operator

Hello, and welcome. My name is Alex, and I will be your conference facilitator today for the Amgen analyst and investor conference call from the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease Conference. (Operator Instructions) I would now like to introduce David Reese, Executive Vice President of Research and Development. Dr. Reese, you may now begin.

David M. Reese – Amgen Inc. – EVP of Research & Development

Thanks, Alex, and good morning, everyone. Thanks for joining us for an update on the AMG 133 program in obesity and allied disorders. These are review of data just presented at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.

Next slide, please. Here’s our standard safe harbor disclaimer. I did note that these slides are up on our website now for those who wish to follow along.

Next slide, please. In terms of today’s agenda, I will provide a brief introduction to our strategy in obesity and allied disorders following which Narimon, the Head of our cardiometabolic group in clini

MORE IN INSIDE INVESTMENT NEWS

Lululemon stock Plunges 20%: A Portfolio Warning for Retail Investors

Published: Friday, September 4, 2026 · 9:21 AM

Broadcom’s AI Growth: Alpha Potential in Next-Gen Chips

Published: Thursday, September 3, 2026 · 12:35 AM